New York City, NY, Dec. 27, 2025 (GLOBE NEWSWIRE) -- IntroAs medical weight loss continues to evolve in 2026, the landscape of GLP-1 therapies has reached a pivotal moment with expanded FDA-recognized access pathways, emerging treatment formats, and enhanced clinical support structures designed t... Read more
Benzinga - Dec 27
All my friends are disappearing this Christmas thanks to weight-loss jabs Read more
The Times - Dec 08
A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular protection—reducing heart attack, stroke, and death in adults with type 2 diabetes. While companies have claimed large differences favoring their own medications, researchers f... Read more
Science Daily - Nov 22
Semaglutide lowered the risk of major adverse cardiovascular events across all body weight and waist circumference levels in people with overweight or obesity and cardiovascular disease. Early waist reduction explained only a third of this benefit, showing that semaglutide’s heart protection exte... Read more
Medical News - Oct 26
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before. Read more
Medical News - Sep 16
"For them to work effectively, they need to be taken long term," cautioned epidemiologisy professor Reimar W. Thomsen. Read more
Newsweek - Sep 13
From cancer drugs to diabetes therapies, WHO's new list expands access to modern medicines and boosts the push for global healthcare equity Read more
Business Standard - Sep 08
